Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426) Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Cheng, A. L.; Meyer, T.; El-Khouelry, A. B.; Ikeda, M.; Chun, H. G.; Falvre, S. J.; Furuse, J.; Knox, J. J.; Okusaka, T.; Ping, J.; Borgman-Hagey, A. E.; Kelley, R. K. |
| Abstract Title: | Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426) |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613202099 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.tps4150 |
| Notes: | Meeting Abstract: TPS4150 -- 50th Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 30-JUN 03, 2014 -- Chicago, IL -- S -- Source: Wos |
